These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608 [No Abstract] [Full Text] [Related]
13. Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review. Kyle K; Bronstein JM Parkinsonism Relat Disord; 2020 Jun; 75():55-62. PubMed ID: 32480308 [TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden. Fredericks D; Norton JC; Atchison C; Schoenhaus R; Pill MW Am J Manag Care; 2017 Apr; 23(5 Suppl):S83-S92. PubMed ID: 28715903 [TBL] [Abstract][Full Text] [Related]
15. Treatment of Psychosis in Parkinson's disease and sudden death. Kyle K; Bronstein JM Parkinsonism Relat Disord; 2020 Oct; 79():127. PubMed ID: 32943345 [No Abstract] [Full Text] [Related]
16. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. Sahli ZT; Tarazi FI Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301 [TBL] [Abstract][Full Text] [Related]
17. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Kianirad Y; Simuni T Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967 [TBL] [Abstract][Full Text] [Related]
18. Pimavanserin: An Inverse Agonist Antipsychotic Drug. Howland RH J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248 [TBL] [Abstract][Full Text] [Related]
19. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
20. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]